Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial
Exscientia paid $20m in upfront cash and equity to buy its development partner GT Apeiron’s shares for the CDK7 inhibitor.
Exscientia paid $20m in upfront cash and equity to buy its development partner GT Apeiron’s shares for the CDK7 inhibitor.
What's Your Reaction?
